{"slug":"resistance","tag":"resistance","variants":["resistance"],"description":"No description yet","count":6,"kinds":{"target":1,"person":2,"biomarker":3},"related":[{"slug":"biomarker","tag":"biomarker","shared":3},{"slug":"adc-target","tag":"adc-target","shared":1},{"slug":"cml","tag":"cml","shared":1},{"slug":"colorectal","tag":"colorectal","shared":1},{"slug":"ctdna","tag":"ctdna","shared":1},{"slug":"dna-repair","tag":"dna-repair","shared":1},{"slug":"egfr","tag":"egfr","shared":1},{"slug":"hormone-receptor","tag":"hormone-receptor","shared":1},{"slug":"parp","tag":"parp","shared":1}],"records":[{"id":"her3","kind":"target","name":"HER3","route":"/targets/her3/","tldr":"HER3 is a cousin of HER2 that cancers use as an escape route when HER2 or EGFR are blocked."},{"id":"alberto-bardelli","kind":"person","name":"Alberto Bardelli","route":"/people/alberto-bardelli/","tldr":"Used ctDNA to show how colorectal cancers evolve resistance to EGFR antibodies and how that resistance can fade."},{"id":"alan-dandrea","kind":"person","name":"Alan D. D'Andrea","route":"/people/alan-dandrea/","tldr":"Mapped the Fanconi anaemia/BRCA DNA repair pathway and how tumours become resistant to PARP inhibitors."},{"id":"egfr-t790m","kind":"biomarker","name":"EGFR T790M","route":"/biomarkers/egfr-t790m/","tldr":"T790M is the gatekeeper mutation that lung cancers acquire to escape first- and second-generation EGFR inhibitors. Finding it, in tissue or blood, is the historic gate for osimertinib after an earlier EGFR drug."},{"id":"bcr-abl1-t315i","kind":"biomarker","name":"BCR::ABL1 T315I","route":"/biomarkers/bcr-abl1-t315i/","tldr":"T315I is the gatekeeper mutation in the ABL1 kinase that defeats imatinib, dasatinib, nilotinib and bosutinib. Ponatinib and asciminib are the two drugs approved for it."},{"id":"esr1-mutation-ctdna","kind":"biomarker","name":"ESR1 mutation (ligand-binding domain, usually in ctDNA)","route":"/biomarkers/esr1-mutation-ctdna/","tldr":"ESR1 mutations arise in the oestrogen receptor's ligand-binding domain after aromatase inhibitor treatment, letting the receptor work without oestrogen. They are usually found in a blood test and select the oral SERDs elacestrant and imlunestrant."}]}